Back to top
more

Clearside Biomedical, Inc. (CLSD)

(Delayed Data from NSDQ)

$1.73 USD

1.73
108,209

+0.04 (2.37%)

Updated Sep 18, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.44%
2Buy17.91%
3Hold9.42%
4Sell4.91%
5Strong Sell1.79%
S&P50010.66%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 23% (194 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0.00% and -75.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Upgraded to Buy: Here's What You Should Know

Clearside Biomedical, Inc. (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Clearside Biomedical Inc (CLSD) Reports Q1 Loss, Tops Revenue Estimates

Clearside Biomedical Inc (CLSD) delivered earnings and revenue surprises of 22.22% and 2.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -75.00% and -67.06%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Clearside Biomedical, Inc. (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Clearside Biomedical Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Clearside Biomedical.

Sweta Killa

Biotech Leading in Q4: Best ETFs & Stocks

We highlight five biotech ETFs and stocks that are leading the market in Q4.

Zacks Equity Research

Is the Options Market Predicting a Spike in Clearside Biomedical (CLSD) Stock?

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -6.25% and 182.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More

Key highlights of the past week include drug approvals, and other regulatory and pipeline news.

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Misses Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 59.46% and -10.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Options Traders Expect Huge Moves in Clearside Biomedical (CLSD) Stock

Clearside Biomedical (CLSD) needs investors to pay close attention to the stock based on moves in the options market lately.

Zacks Equity Research

Surging Earnings Estimates Signal Good News for Clearside (CLSD)

Clearside (CLSD) is seeing positive earnings estimate revisions suggesting that it could be a solid choice for investors.

Zacks Equity Research

Clearside BioMedical (CLSD) is Oversold: Can It Recover?

Clearside BioMedical, Inc. (CLSD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock